Optimizing AAV Manufacture Purification
By Orjana Terova, Senior Product Manager, Purification, and Zoltan Gulyas, Senior Field Applications Specialist, Purification
Gene therapies show the potential to revolutionize the field of medicine. Adeno-associated viruses have emerged as the vector of choice for delivering therapeutic genes, but manufacturing processes need to be improved and optimized. Today’s gene therapy developers are using scalable techniques from the beginning of development, and recognize the need to not only improve productivity but also process robustness and reproducibility. At the same time, regulatory agencies are expecting increasingly established product control and characterization.
Learn more about the evolution of gene therapies, advice and points to consider regarding affinity capture of AAVs, and technology being explored to unlock AAV's full potential.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.